Pharmaceutical Intermediates
- • Analgesics (56)
- • Anesthetics (52)
- • Anti-Addiction Agents (8)
- • Antibacterials (117)
- • Anticonvulsants (20)
- • Antidementia Agents (23)
- • Antidepressants (35)
- • Antiemetics (24)
- • Antifungals (24)
- • Antigout Agents (9)
- • Anti-inflammatory Agents (28)
- • Antimigraine Agents (21)
- • Antineoplastics (427)
- • Antiparasitics (11)
- • Antiparkinson Agents (28)
- • Antipsychotics (54)
- • Antispasticity Agents (12)
- • Antivirals (146)
- • Anxiolytics (16)
- • Blood Glucose Regulators (105)
- • Blood Products (61)
- • Cardiovascular Agents (179)
- • CNS Agents (22)
- • Dental and Oral Agents (8)
- • Dermatological Agents (19)
- • Electrolytes (15)
- • Gastrointestinal Agents (62)
- • Genetic/Enzyme Disorder (12)
- • Genitourinary Agents (47)
- • Immunological Agents (36)
- • Metabolic Bone Disease (6)
- • Ophthalmic Agents (32)
- • Respiratory Tract (51)
- • Skeletal Muscle Relaxants (5)
- • Sleep Disorder Agents (28)
- • Oled Material Intermediate (333)
- • Heterocyclic Compound (9763)
- • Bulk Drug Intermediates (17716)
Related News
Antifungals
N-BOC-ethylenediamine
(57260-73-8)-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99.5%
$1.2/KG EXW
-
- / 99.00%
-
Industrial Grade / 99%
Request for quotation , get quotes from more suppliers.
More Information
Antifungals are substances used to treat or prevent infections caused by fungi, including yeasts, molds, and dermatophytes. They are widely applied in pharmaceutical formulations, hospital treatments, and research on systemic and superficial fungal infections.
Key mechanisms of action for antifungals include:
• Azoles – Inhibit fungal ergosterol synthesis, disrupting cell membrane integrity.
• Polyenes – Bind to ergosterol in fungal membranes, causing cell leakage and death.
• Echinocandins – Block fungal cell wall synthesis by inhibiting β-(1,3)-D-glucan synthase.
• Allylamines – Inhibit squalene epoxidase, leading to toxic accumulation inside fungal cells.
Factors to consider when selecting antifungal raw materials:
• Type and severity of infection – systemic, superficial, or dermatophyte infections.
• Safety and tolerability – side effects, patient age, and potential drug interactions.
• Formulation requirements – solubility, stability, and compatibility for tablets, creams, or injectables.
• Regulatory compliance – adherence to pharmaceutical safety standards and clinical guidelines.
Common antifungal raw materials include fluconazole, itraconazole, amphotericin B, ketoconazole, and terbinafine. They are typically supplied in powder or crystalline forms suitable for oral, topical, or injectable formulations. These agents are essential for clinical therapy, pharmaceutical development, and research on fungal diseases.
Frequently Asked Questions
Antifungals are medications used to treat fungal infections by either killing fungi or inhibiting their growth. They work by targeting components unique to fungal cells—such as ergosterol in the cell membrane or enzymes involved in cell wall synthesis—without significantly affecting human cells. Common classes include azoles, polyenes, echinocandins, and allylamines, each with specific mechanisms and applications.
Antifungal agents are widely used to treat a range of fungal infections, including superficial conditions like athlete’s foot, ringworm, and yeast infections, as well as systemic infections such as candidiasis, aspergillosis, and cryptococcal meningitis. They are essential in immunocompromised patients, such as those undergoing chemotherapy or living with HIV/AIDS, where fungal infections can be life-threatening.
When selecting an antifungal Active Pharmaceutical Ingredient (API) supplier, consider the following: compliance with international standards like GMP and ISO certifications, robust quality control systems including analytical testing and documentation, regulatory approvals from agencies like the FDA or EMA, consistent production capacity, and a track record of supplying to reputable pharmaceutical companies. Technical support and regulatory dossier availability (e.g., DMF or CEP) are also critical factors.
Manufacturing antifungal compounds presents several challenges, including complex multi-step syntheses that require precise reaction control, handling of hazardous reagents, and managing stereochemistry for chiral molecules. Additionally, ensuring consistent purity while minimizing genotoxic impurities is critical. Regulatory scrutiny is high due to the therapeutic importance of antifungals, making process validation, environmental controls, and supply chain transparency essential for compliant production.